Sarepta launched an additional Phase 3 trial intended to address European Medicines Agency concerns about Elevidys for Duchenne muscular dystrophy. The EMA previously denied marketing authorization after EMBARK did not meet endpoints tied to movement abilities, and the new registration-enabling study is designed to generate additional placebo-controlled efficacy and safety data over 72 weeks, with Roche overseeing the program in partnership.